Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SNCA | P37840 | 1/20 | 0.38 |
| ▸ | GABRP | O00591 | 1/20 | 0.38 |
| ▸ | GABRD | O14764 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7563232 | 0.86 | ALDH1A1 (0.72) | ALDH1A1HSD17B10TSHRCYP3A4KDM4E | |
| SCHEMBL17368442 | 0.85 | ALDH1A1 (0.55) | ALDH1A1HSD17B10TSHRCYP3A4KDM4E | |
| SCHEMBL55681 | 0.82 | ALDH1A1 (0.61) | ALDH1A1HSD17B10TSHRCYP3A4HPGD | |
| SCHEMBL11181389 | 0.80 | CYP3A4 (0.73) | ALDH1A1HSD17B10TSHRCYP3A4KDM4E | |
| SCHEMBL8786921 | 0.80 | ALDH1A1 (0.63) | ALDH1A1HSD17B10TSHRCYP3A4KDM4E | |
| SCHEMBL10587756 | 0.79 | ALDH1A1 (0.57) | ALDH1A1HSD17B10TSHRCYP3A4KDM4E | |
| SCHEMBL9789268 | 0.78 | ALDH1A1 (0.52) | ALDH1A1HSD17B10TSHRCYP3A4KDM4E | |
| SCHEMBL3945760 | 0.77 | ALDH1A1 (0.55) | ALDH1A1HSD17B10TSHRCYP3A4KDM4E | |
| SCHEMBL10486967 | 0.77 | ALDH1A1 (0.55) | ALDH1A1HSD17B10TSHRCYP3A4KDM4E | |
| SCHEMBL17368427 | 0.77 | CYP3A4 (0.50) | ALDH1A1HSD17B10TSHRCYP3A4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2675453-B1 | METHODS FOR CONTROLLING PAIN IN CANINES USING A TRANSDERMAL SOLUTION OF FENTANYL | ELANCO US INC (US) | 2018-08-08 | — | — | EP | claimed |
| US-20170128462-A1 | METHODS FOR TREATING FEMALE SEXUAL DYSFUNCTION WHILE DECREASING CARDIOVASCULAR RISK | ANI PHARMACEUTICALS, INC. | 2017-05-11 | — | — | US | claimed |
| EP-2675453-A1 | METHODS FOR CONTROLLING PAIN IN CANINES USING A TRANSDERMAL SOLUTION OF FENTANYL | ELI LILLY AND CO. (US) | 2013-12-25 | — | — | EP | claimed |
| EP-2675454-A1 | METHODS FOR CONTROLLING PAIN IN EQUINES USING A TRANSDERMAL SOLUTION OF FENTANYL | ELI LILLY AND CO. (US) | 2013-12-25 | — | — | EP | claimed |
| US-20120322828-A1 | METHODS FOR CONTROLLING PAIN IN EQUINES USING A TRANSDERMAL SOLUTION OF FENTANYL | ELI LILLY AND COMPANY (US) | 2012-12-20 | — | — | US | claimed |
| WO-2012112355-A1 | METHODS FOR CONTROLLING PAIN IN EQUINES USING A TRANSDERMAL SOLUTION OF FENTANYL | ELI LILLY AND COMPANY (US) | 2012-08-23 | — | — | WO | claimed |
| WO-2012112348-A1 | METHODS FOR CONTROLLING PAIN IN CANINES USING A TRANSDERMAL SOLUTION OF FENTANYL | ELI LILLY AND COMPANY (US) | 2012-08-23 | — | — | WO | claimed |
| US-20120208849-A1 | METHODS FOR CONTROLLING PAIN IN CANINES USING A TRANSDERMAL SOLUTION OF FENTANYL | ELI LILLY AND COMPANY (US) | 2012-08-16 | — | — | US | claimed |
| US-20120022033-A1 | Methods for decreasing cardiovascular risk in postmenopausal women | BIOSANTE PHARMACEUTICALS, INC. (US) | 2012-01-26 | — | — | US | claimed |
| US-20120004204-A1 | Methods for treating sexual dysfunction while decreasing cardiovascular risk | BIOSANTE PHARMACEUTICALS, INC. (US) | 2012-01-05 | — | — | US | claimed |
| US-20080131494-A1 | Dermal Penetration enhancers and drug delivery systems involving same | ACRUX DDS PTY LTD. | 2008-06-05 | — | — | US | claimed |
| EP-1769785-A1 | Dermal penetration enhancers and drug delivery systems involving same | Acrux DDS Pty Ltd (AU) | 2007-04-04 | — | — | EP | claimed |
| EP-1674068-A1 | Dermal penetration enhancers and drug delivery systems involving same | Acrux DDS Pty Ltd (AU) | 2006-06-28 | — | — | EP | claimed |
| US-6818226-B2 | DERMAL PENETRATION ENHANCER IS A SAFE SKIN-TOLERANT ESTER SUNSCREEN. | ACRUX DDS PTY. LTD. (AU) | 2004-11-16 | — | — | US | claimed |
| US-20040146469-A1 | Dermal penetration enhancers and drug delivery systems involving same | MONASH UNIVERSITY | 2004-07-29 | — | — | US | claimed |
| US-20020028235-A1 | Dermal penetration enhancers and drug delivery systems involving same | ACRUX DDS PTY LTD. (AU) | 2002-03-07 | — | — | US | claimed |
| US-6299900-B1 | NON-OCCLUSIVE, PERCUTANEOUS OR TRANSDERMAL DRUG DELIVERY SYSTEM | MONASH UNIVERSITY (AU) | 2001-10-09 | — | — | US | claimed |
| EP-0901368-A4 | DERMAL PENETRATION ENHANCERS AND DRUG DELIVERY SYSTEMS INVOLVING SAME | UNIV MONASH (AU) | 2000-01-26 | — | — | EP | claimed |
| EP-0901368-A1 | DERMAL PENETRATION ENHANCERS AND DRUG DELIVERY SYSTEMS INVOLVING SAME | MONASH UNIVERSITY (AU) | 1999-03-17 | — | — | EP | claimed |
| WO-1997029735-A1 | DERMAL PENETRATION ENHANCERS AND DRUG DELIVERY SYSTEMS INVOLVING SAME | MONASH UNIVERSITY (AU) | 1997-08-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028235-A1 | Dermal penetration enhancers and drug delivery systems involving same | CUTA, ABCG2, SLC16A8 | ALDH1A1 621/4885HSD17B10 885/4885TSHR 3353/4885 |
| US-20080131494-A1 | Dermal Penetration enhancers and drug delivery systems involving same | SLC46A1, SLC33A1, SLC19A1 | ALDH1A1 356/4885HSD17B10 619/4885TSHR 4546/4885 |
| US-20120208849-A1 | METHODS FOR CONTROLLING PAIN IN CANINES USING A TRANSDERMAL SOLUTION OF FENTANYL | OPRL1, OPRK1, TRPV1 | ALDH1A1 1854/4885HSD17B10 3355/4885TSHR 3144/4885 |
| US-20040146469-A1 | Dermal penetration enhancers and drug delivery systems involving same | SLC46A1, SLC33A1, SLC19A1 | ALDH1A1 356/4885HSD17B10 619/4885TSHR 4546/4885 |
| US-20120322828-A1 | METHODS FOR CONTROLLING PAIN IN EQUINES USING A TRANSDERMAL SOLUTION OF FENTANYL | OPRL1, OPRK1, S100P | ALDH1A1 1121/4885HSD17B10 2437/4885TSHR 3277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.